Drug Profile
Research programme: antibacterial therapeutics - Advanced Life Sciences/University of British Columbia
Latest Information Update: 06 May 2011
Price :
$50
*
At a glance
- Originator University of British Columbia
- Developer Advanced Life Sciences; University of British Columbia
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Gram-negative infections; Gram-positive infections
Most Recent Events
- 06 May 2011 Suspended for Gram-negative infections in Canada (unspecified route)
- 06 May 2011 Suspended for Gram-positive infections in Canada (unspecified route)
- 26 Jul 2010 Early research in Gram-positive infections in Canada (unspecified route)